Clover Health Investments, Corp (CLOV)

Clover Health Investments, Corp's Q·Score is 4.7/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Revenue expanding at 62% year-over-year. Key area to monitor: currently unprofitable (-3% margin). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.

The consensus price target for CLOV is $4.15, based on ratings from 3 Wall Street analysts. This is 12.9% below the current price of $4.76. Price targets are forward-looking estimates and not guarantees of future performance.

Clover Health Investments, Corp (CLOV) scores below peers on valuation metrics, trading above typical sector multiples. Its forward P/E ratio stands at 47.6×. The consensus analyst price target of $4.15 is 13% below the current price.

Clover Health Investments, Corp's next earnings report is expected on approximately August 4, 2026.

Clover Health Investments, Corp has a net profit margin of -2.6%, indicating the company is currently operating at a net loss. Its gross margin stands at 18.4%, reflecting a more cost-intensive business model.

Clover Health Investments, Corp is reporting strong year-over-year growth of 62.0%.